Can a GABA Supplement Help With Benzodiazepine Withdrawal?

A GABA capsule does very little, and the reason is in the receptor.

People in the middle of a benzodiazepine taper search for GABA at all hours, usually after a hard night. The honest answer is short. In Dr. Leeds’ experience, no supplement does what a slow, medically supervised taper does, and a GABA capsule does very little at all.

Gamma-aminobutyric acid (GABA) is the brain’s main calming chemical messenger, the signal that tells overactive nerve cells to settle. Benzodiazepines such as Xanax (alprazolam), Klonopin (clonazepam), Ativan (lorazepam) and Valium (diazepam) work through it, and so do the z-drugs used for sleep, such as Ambien (zolpidem). It is natural to assume that a bottle of GABA would put back whatever the drug took away.

Unfortunately, that assumption gets the biology backward. To see why, look at what a benzodiazepine actually does inside the brain.

Benzodiazepines act on the GABA receptor, not on the GABA supply.

GABA does its work by attaching to a receptor on the nerve cell, the GABA type A receptor, known as the GABA-A receptor. When GABA lands there, a channel opens, chloride ions flow into the cell, and the cell becomes harder to excite. The Ashton Manual, in Chapter I under “Mechanisms of action”, calls the benzodiazepine a booster to the actions of GABA.

That word matters. In fact, a benzodiazepine does not add GABA or replace it. It binds to its own site on the same receptor and makes the receptor respond more strongly to the GABA the brain already makes.

An analogy may help, though it is not a perfect one. Think of GABA as a singer and the receptor as the sound system in a hall. A benzodiazepine does not add singers. It turns up the amplifier, so the same voice fills the room.

Withdrawal is receptor adaptation, not GABA depletion.

Over weeks and months, the brain adjusts to the amplifier. The Manual’s Chapter I section on tolerance explains that compensatory changes occur in the receptors, which become less responsive, so the calming actions of GABA and of the drug both decrease. In the hall, the crew has turned the house speakers down to keep the volume normal.

Now pull the amplifier out in one move. The room goes nearly silent, even though the singer never stopped singing. That is withdrawal: the receptors are still turned down, the excitatory systems they were holding in check rebound, and the nervous system runs hot. Chapter III of the Manual, under “Mechanisms of withdrawal reactions”, says that rapid removal of the drug opens the floodgates.

So, the idea of tapering by topping up GABA, and the notion of GABA depletion, both point at the wrong part of the system. Nothing has been used up. The Supplement to the Ashton Manual, in its section on nutritional supplements, states it plainly: benzodiazepines do not decrease GABA concentrations, they alter GABA-receptor affinity, and this slowly reverses without supplements.

How hard withdrawal hits depends on the drug, the dose, how long it was taken and how fast it leaves the body. With a short-acting drug such as Xanax, symptoms can begin within hours of a missed dose, and with a long-acting drug it can take days. Some symptoms can be protracted, lasting months or longer, and they still tend to fade as the receptors readjust.

Does oral GABA even reach the brain?

Nobody knows for certain. Even so, that is the honest starting point: GABA taken by mouth is a small, water-soluble molecule, and whether it crosses the blood-brain barrier in any meaningful amount is unsettled. What evidence exists for a calming effect is limited and modest, and GABA is sold as a dietary supplement, not as an approved medicine.

The Manual’s Supplement goes further: taking GABA precursors does not increase GABA concentrations in the brain, and there is no evidence that supplements speed the process. Chapter III, under “Diet, fluids and exercise”, adds that there is no general need for dietary supplements or extra vitamins or minerals, and that all of these can be harmful in excess.

Clinical experience says the same. Patients who have tried GABA describe, at most, a mild calm that could just as easily be expectation, and in Dr. Leeds’ experience it has not changed the course of a taper. Going back to the hall, the new singers may never get past the front door, and the speakers would still be turned down if they did.

No supplement replaces a slow taper.

Fortunately, the house speakers do come back up, and a slow taper is how the amplifier is turned down at the pace they can follow. The Ashton Manual, written by Professor C. Heather Ashton, sets that pace in Chapter II under “Dosage tapering”: the precise rate of withdrawal is an individual matter, the patient sets it, and whether it takes six, twelve or eighteen months matters little after years of use. Many patients who set their own pace find, in the Manual’s words, that there is little or no agony involved.

Two tools shape the taper. Where it helps, the Manual’s crossover taper moves a patient from a short-acting benzodiazepine to diazepam, whose long half-life lets the blood level fall smoothly instead of in daily peaks and troughs. And, the Maudsley Deprescribing Guidelines describe hyperbolic dose reductions, in which each step is a smaller amount than the one before, because the last milligrams carry a disproportionate share of the receptor effect.

The shape is a curve that flattens near the end, not a straight line, and the exact steps are worked out between patient and physician. Above all, stopping abruptly is the one thing that must not happen. In September 2020 the United States Food and Drug Administration (FDA) updated the boxed warning on every benzodiazepine label to state that abrupt discontinuation or rapid dosage reduction can bring on acute withdrawal reactions, including seizures, that can be life-threatening.

A seizure is a medical emergency: call emergency services for a seizure or any other medical emergency. Slow tapering exists so that it never comes to that.

Tell Dr. Leeds about every supplement, because sedating products stack.

Many patients reach for the supplement aisle because a prescription is what hurt them, and something from a health-food store feels safer than anything a doctor might suggest. That distrust is understandable. Yet, the supplement industry has never met a receptor it could not promise to fix, and some of what it sells acts on the very receptor being tapered.

Anything sedating adds to benzodiazepine sedation. When a new symptom appears mid-taper, patient and physician need to know whether it came from the taper or the new bottle, and a sedating product muddies that answer. The Manual’s Supplement lists valerian, kava, melatonin and GABA itself among products that patients have reported as unhelpful or harmful.

Phenibut, sold online as a calming supplement, is a drug that acts on GABA receptors and causes its own dependence and withdrawal, and kava and high-dose valerian deepen sedation. The safest rule is simple: every supplement, every herb and every over-the-counter sleep aid goes on the list Dr. Leeds sees.

What about the other calming supplements patients try?

Patients ask about L-theanine, melatonin, magnesium, chamomile and passionflower. Evidence for any of them in benzodiazepine withdrawal is limited, and none has shortened a taper in Dr. Leeds’ experience. Some patients describe them as pleasant, and pleasant is not nothing during a hard stretch.

While a cup of chamomile tea is unlikely to cause trouble, the rule does not change. Anything sedating, melatonin and valerian included, is disclosed before it is started, so it cannot mask or complicate what the taper is doing. Some supplements do help some patients, and that is a decision for the patient and a physician who knows the pharmacology, not a blanket yes or no.

In the end, what helps more than any capsule is unglamorous: regular sleep and wake times, gentle daily movement, the normal diet the Manual recommends, and a plan that does not change on a bad day. Time does the rest.

Dependence on a prescribed benzodiazepine is a medical condition.

People go looking for a cleanse or a supplement partly because they have been told they have an addiction to fix. A person who took a benzodiazepine as prescribed and now cannot stop without symptoms has physical dependence, a medical condition caused by the medication, and dependence is not addiction. It is not treated with willpower or a bottle from a health-food store.

It is treated with a gradual, patient-directed taper adapted to the person, over months and sometimes longer. That taper is also the exit plan that belonged in the conversation the day the prescription was written: risks first, the alternatives, how the drug would eventually be stopped, and the right to say no at any point. When it was never offered, it can still be built now.

How Dr. Leeds handles the GABA question in a taper.

Dr. Leeds’ practice in Fort Lauderdale offers medically supervised benzodiazepine and z-drug tapering by telemedicine for patients in Florida, on a concierge basis rather than through insurance, and one physician sees every patient. When a patient brings up GABA, he explains the receptor, asks what else is in the cabinet, and turns the conversation back to the pace of the taper, with the Ashton Manual and the Maudsley guidance as the framework. He also helps patients taper other psychiatric medications.

If the supplement question has been keeping you up mid-taper, bring it to a physician who treats dependence as the medical condition it is. Contact Dr. Leeds through the practice’s contact form.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.